We commend Melina Arnold and colleagues on the ICBP SURVMARK-2 project published in The Lancet Oncology, which concluded that cancer survival has improved over the past two decades (1995–2014) across seven high-income countries because of earlier diagnosis and advancements in tailored treatments based on molecular markers.A noteworthy finding was that survival is persistently lower in the UK and Denmark compared with the other countries for four common cancer types.
